drugset / Trial / NCT07493512
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2026-04-28
- Primary completion
- 2028-01-30
- Completion
- 2030-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Xaluritamig | Unknown | — | Intravenous |